Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + atezolizumab vs sorafenib in advanced hepatocellular carcinoma (first-line)
2024-516479-34-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised trial of cabozantinib, atezolizumab and sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Exelixis, Inc. Primary endpoints: Progression-free survival (PFS) by BIRC (cabozantinib + atezolizumab vs sorafenib) and Overall survival (OS) (cabozantinib + atezolizumab vs sorafenib). Planned start May 2019; status: authorised.
02
Drugs
cabozantinibatezolizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-516479-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516479-34-00.